Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
Hongchao Pan, Richard Peto, Quarraisha Abdool Karim, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 431

Showing 1-25 of 431 citing articles:

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
Goran Kokić, Hauke S. Hillen, Dimitry Tegunov, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 533
Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?
Varnica Bajaj, Nirupa Gadi, Allison P. Spihlman, et al.
Frontiers in Physiology (2021) Vol. 11
Open Access | Times Cited: 431
Severe covid-19 pneumonia: pathogenesis and clinical management
Amy Attaway, Rachel G. Scheraga, Adarsh Bhimraj, et al.
BMJ (2021), pp. n436-n436
Open Access | Times Cited: 366
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update
Waleed Alhazzani, Laura Evans, Fayez Alshamsi, et al.
Critical Care Medicine (2021) Vol. 49, Iss. 3, pp. e219-e234
Open Access | Times Cited: 360
Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects
Dina Visca, Ong C, Simon Tiberi, et al.
Pulmonology (2021) Vol. 27, Iss. 2, pp. 151-165
Open Access | Times Cited: 282
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 272
Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys
Kailu Wang, Eliza Lai‐Yi Wong, Kin‐Fai Ho, et al.
Vaccines (2021) Vol. 9, Iss. 1, pp. 62-62
Open Access | Times Cited: 269
SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development
Nicholas Murgolo, Alex G. Therien, Bonnie J. Howell, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 2, pp. e1009225-e1009225
Open Access | Times Cited: 204
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
Remdesivir for the treatment of COVID-19
Kelly Ansems, Felicitas Grundeis, Karolina Dahms, et al.
Cochrane library (2021) Vol. 2021, Iss. 8
Open Access | Times Cited: 194
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19
Bhagteshwar Singh, Hannah Ryan, Tamara Kredo, et al.
Cochrane library (2021) Vol. 2021, Iss. 2
Open Access | Times Cited: 190
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Dharma Rao Tompa, Aruldoss Immanuel, Srimari Srikanth, et al.
International Journal of Biological Macromolecules (2021) Vol. 172, pp. 524-541
Open Access | Times Cited: 184
Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
Katerina Naydenova, Kyle Muir, Long-Fei Wu, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 7
Open Access | Times Cited: 172
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
Jesper Damsgaard Gunst, Nina Breinholt Stærke, Marie H. Pahus, et al.
EClinicalMedicine (2021) Vol. 35, pp. 100849-100849
Open Access | Times Cited: 168
Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19
I Bernard, Daniel Limonta, Lara K. Mahal, et al.
Viruses (2020) Vol. 13, Iss. 1, pp. 29-29
Open Access | Times Cited: 160
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
Karim Ali, Tanweer Azher, Mahin Baqi, et al.
Canadian Medical Association Journal (2022) Vol. 194, Iss. 7, pp. E242-E251
Open Access | Times Cited: 146
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
Yingjun Li, Liu Cao, Ge Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2785-2793
Closed Access | Times Cited: 124
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Iván O. Rosas, George Diaz, Robert Gottlieb, et al.
Intensive Care Medicine (2021) Vol. 47, Iss. 11, pp. 1258-1270
Open Access | Times Cited: 115
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
Malina A. Bakowski, Nathan Beutler, Karen C. Wolff, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 112
SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon
Maya Shemesh, Turgut E. Aktepe, Joshua M. Deerain, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 8, pp. e1009800-e1009800
Open Access | Times Cited: 112
Remdesivir for the treatment of COVID-19
Felicitas Grundeis, Kelly Ansems, Karolina Dahms, et al.
Cochrane library (2023) Vol. 2023, Iss. 1
Closed Access | Times Cited: 77
Therapeutics for COVID-19 and post COVID-19 complications: An update
Debdoot Basu, Vivek P. Chavda, Anita A. Mehta
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100086-100086
Open Access | Times Cited: 68
Covid-19: Remdesivir has little or no impact on survival, WHO trial shows
Owen Dyer
BMJ (2020), pp. m4057-m4057
Open Access | Times Cited: 128
Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety
Peter Breining, Anne Lier Frølund, Jesper Falkesgaard Højen, et al.
Basic & Clinical Pharmacology & Toxicology (2020) Vol. 128, Iss. 2, pp. 204-212
Open Access | Times Cited: 127
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties
Michael A. Matthay, Bruce Thompson
The Lancet Respiratory Medicine (2020) Vol. 8, Iss. 12, pp. 1170-1172
Open Access | Times Cited: 112
Page 1 - Next Page

Scroll to top